Thierry Fontanges

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis

Christophe Hézode, Hélène Fontaine, Céline Dorival et al. · Gastroenterology · 2014 · 260 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis

Xavier Causse, Hubert Godinot, Michèle Chevallier et al. · Gastroenterology · 1991 · 248 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +11

Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia

Mathilde Di Filippo, Philippe Moulin, Pascal Roy et al. · Journal of Hepatology · 2014 · 146 citations

Life Sciences, Genetics, Molecular Genetics +17

Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study

Patrick Marcellin, M Chousterman, Thierry Fontanges et al. · Liver International · 2011 · 75 citations

Pharmacy, Internal Medicine, Pharmacotherapy +17